Two Strategies for Methicillin-resistant Staphylococcus Aureus (MRSA) Infection Prevention in Surgical Patients (MOSAR-04)

This study has been completed.
Sponsor:
Collaborator:
European Commission
Information provided by (Responsible Party):
Stephen Harbarth, University Hospital, Geneva
ClinicalTrials.gov Identifier:
NCT00685867
First received: May 27, 2008
Last updated: August 20, 2012
Last verified: August 2012
  Purpose

The study is a two-arm controlled multi-centre trial of two strategies to reduce nosocomial MRSA transmission and infection among surgical patients. Enrolment and primary analyses will be performed at the hospital level. A total of ten adult surgical departments with at least 3 surgical subspecialties each will participate in the study. Sites of the study are located in 9 countries (UK, France, Spain, Germany, Switzerland, Italy, Serbia, Greece and Israel).

The primary objective is to determine the effect of an early MRSA detection & decolonization & isolation strategy compared to an enhanced standard control strategy on healthcare-associated MRSA isolation rates among surgical patients at risk of MRSA carriage, who are hospitalized for at least 24 hours.


Condition Intervention
MRSA Infection
Other: Rapid molecular MRSA test
Behavioral: Hand hygiene promotion

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: An Interventional Study to Evaluate the Impact of Two Innovative Strategies in Preventing Nosocomial MRSA Infection in Surgical Patients

Resource links provided by NLM:


Further study details as provided by University Hospital, Geneva:

Primary Outcome Measures:
  • Nosocomial MRSA isolation rate (expressed as the monthly rate of MRSA in clinical isolates divided by the number of susceptible patients per hundred) [ Time Frame: Monthly ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Nosocomial MRSA infection rate (= number of nosocomial MRSA infections per 100 admissions) [ Time Frame: Monthly ] [ Designated as safety issue: No ]

Enrollment: 126750
Study Start Date: May 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Rapid detection
Other: Rapid molecular MRSA test
PCR-based rapid screening for MRSA carriage
2
Enhanced infection control
Behavioral: Hand hygiene promotion
  • Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance
  • Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)
  • Isolation precautions according to the hospitals' capacity and strategy
  • Additional basic infection control interventions (if necessary)

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Surgical patients with LOS>24h

Exclusion Criteria:

  • Surgical patients with LOS<24h
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00685867

Locations
Switzerland
Geneva University Hospitals
Geneva, Switzerland, 1211
Sponsors and Collaborators
University Hospital, Geneva
European Commission
  More Information

No publications provided

Responsible Party: Stephen Harbarth, Professor, University Hospital, Geneva
ClinicalTrials.gov Identifier: NCT00685867     History of Changes
Other Study ID Numbers: LSHP-CT-037940, LSHP-CT-037940
Study First Received: May 27, 2008
Last Updated: August 20, 2012
Health Authority: Switzerland: Swissmedic

Keywords provided by University Hospital, Geneva:
Staphylococcus aureus
Resistance
Prevention

Additional relevant MeSH terms:
Infection
Communicable Diseases
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on October 01, 2014